Teva Pharmaceutical Industries (NYSE: TEVA) is an interesting investment story. For the right investor, it could be an attractive buy. For me, however, it isn't. Here's the opportunity that Teva has ...

Amneal Pharmaceuticals (NASDAQ:AMRX) reported fourth-quarter and full-year 2025 results and outlined its 2026 outlook, ...

As one long-running feud over the controversial generic drug carveout known as “skinny” labeling comes to a close, the United States’ top lawyer is urging the Supreme Court to reverse a recent ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best strong buy healthcare stocks to invest in.

Allspring SMID Cap Growth Fund reports on Q4 market rotations and performance drivers like Teva and Natera. Read the full ...

Allspring SMID Cap Growth Fund reviews Q4 2025 performance and identifies high-quality growth opportunities. Read the full ...

Eleven community-based organizations were selected as the first recipients of Baltimore City's Opioid Restitution Fund community grants.

Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, ...

He explains why expressing the hard stuff matters: "It made me realize how important communication and support are." ...

U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) said on Friday that the U.S. Food and Drug Administration (FDA) ...